RAN binding protein 9Genealiases: BPM-L · BPM90 · RANBPM · RanBP7
Q-omics provides the consensus-scored RANBP9 profile across patient tissues and cancer cell-line models. RANBP9 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RANBP9 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, RANBP9 RNA expression shows 20,846 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where RANBP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RANBP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RANBP9 survival associations across molecular data types. RANBP9 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RANBP9 RNA expression–survival associations across cancer types. High RANBP9 expression shows unfavorable associations in ACC, LGG and STAD, but favorable associations in KIRC, HNSC and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RANBP9 RNA expression.
This table summarizes RANBP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RANBP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RANBP9 shows lower tumor expression in KICH and higher tumor expression in LIHC, LUAD, BRCA, CHOL and LUSC. The LIHC box plot shows higher RANBP9 RNA expression in tumor versus normal tissue (log2 FC = +0.700, t-test p < 0.001).
This table shows molecular features associated with RANBP9 in patient tissues and cancer cell lines. In patient samples, RANBP9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RANBP9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
